Sino-US artificial intelligence (AI) firm XtalPi Inc. struck a partnership with China-based Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd (HKG: 1177). The two will work together on the development of small-molecule drugs in the liver disease field. No financial details were disclosed.
AI Technology in Drug Discovery
In addition to using AI drug discovery technology to realize the discovery of new small-molecule preclinical candidate compounds, XtalPi will apply its technology to assist in structural prediction work in the early stage of the project. This includes seeking the optimal combined conformation and identifying hot amino acids combined with pocket discovery and more.-Fineline Info & Tech
